Skip to main content
main-content
Top

22-11-2022 | Diabetes | News | Article

approvalsWatch

FDA clears dulaglutide for adolescents

Author: Eleanor McDermid

medwireNews: The FDA has approved extending use of dulaglutide to children and adolescents aged 10 years or older who have type 2 diabetes.

Treatment with the weekly injectable glucagon-like peptide-1 receptor agonist resulted in significant reductions in glycated hemoglobin levels, relative to placebo treatment, among young people aged 10–17 years in the AWARD-PEDS trial, published in June this year.

It did not significantly reduce weight, however.

Dulaglutide is also indicated to reduce glucose levels in adults with type 2 diabetes and to reduce the risk for major adverse cardiovascular events in those at high risk.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group